Dr Benedict Cross, CTO, PhoreMost, explores the drug discovery potential that targeted protein degradation (TPD) offers.   The ubiquitin proteasome pathway (UPP) has been a subject of interest for therapeutic intervention since the first proteasome inhibitors to treat multiple myeloma were developed and approved in 2015. The targeted recruitment of this vital proteostasis pathway to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!